Utilizzo di CRISPR/Cas9 per sviluppare terapie antivirali per l’epatite B
CRISPR/Cas9 technology offers a promising approach for antiviral therapies against Hepatitis B Virus (HBV). By precisely targeting and disrupting viral DNA, CRISPR/Cas9 can effectively inhibit HBV replication and potentially cure chronic infections.





